Five things for pharma marketers to know: Wednesday, May 25, 2016

1. Millions of people are taking antidepressants to treat conditions other than depression, according to a new study. Roughly 55% of prescriptions were written to treat depression, while 45% were used to treat conditions such as anxiety disorder, insomnia, and pain. Authors of the study, published in JAMA, speculated that marketing and word-of-mouth from other physicians may play a role. (CBS News)

2. The FDA will put off a decision on whether to approve Sarepta Therapeutics' experimental drug, eteplirsen, to treat Duchenne muscular dystrophy. Families of patients with the disorder have been pressuring the agency to approve the therapy. (NYT)

3. Eli Lilly and Pfizer are developing a new painkiller that would serve as an alternative to opioid-based treatments. Lilly said the injectable drug, tanezumab, does not have the same abuse potential as opioids. (Reuters)

4. Agrochemical giant Monsanto rejected Bayer's $62 billion acquisition bid, calling it “incomplete and financially inadequate.” JP Morgan analysts believe that the deal is likely to finalize at about $135 billion. (Reuters)

5. ICYMI: The FDA expressed concern about Sanofi's experimental diabetes drug that combines Lantus and Lyxumia. Staff questioned the results of trials that showed the combination had better results when compared to insulin alone. (Bloomberg)